Acute lymphoblastic leukaemia. Acute lymphoblastic leukaemia
Conditions
Interventions
Intervention 1: Intervention group: L-carnitine syrup (?Alborz pharmaceutical company, Iran) with a dose of 50 mg/Kg will be given in three times a day every 8 hours for a period of two months. The c
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children with acute lymphoblastic leukemia (ALL) Age between 5 and 18 years In maintenance phase of chemotherapy (under treatment with methotrexate and 6-mercaptopurine) The serum level of liver enzymes between two and a half to ten times normal Total bilirubin between 1.5 and 3 mg/dL Gamma glutamyl transferase (GGT) serum level greater than or equal to 60 Parental informed consent to participate in the trial
Exclusion criteria
Exclusion criteria: Having viral hepatitis, including A, B and C Active infection with any of the Epstein-Barr viruses, Cytomegalovirus, herpes simplex Active bacterial infection Any type of underlying liver dysfunction Renal dysfunction is defined by a creatinine number higher than 2 times the upper normal level Taking aspirin Contracting AIDS Current Hypothyroidism History of epilepsy Sickle cell anemia Suffering from malabsorption disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of alanine transaminase (ALT). Timepoint: 4, 6, 8, 10 and 12 weeks after the intervention. Method of measurement: Serum spectrophotometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Aspartate transferase (AST) serum level. Timepoint: 4, 6, 8, 10 and 12 weeks after the intervention. Method of measurement: Serum Spectrophotometry.;Blood serum bilirubin level. Timepoint: 4, 6, 8, 10 and 12 weeks after the intervention. Method of measurement: Serum spectrophotometry.;Serum alkaline phosphatase level. Timepoint: 4, 6, 8, 10 and 12 weeks after the intervention. Method of measurement: Serum spectrophotometry.;Blood platelet count. Timepoint: 4, 6, 8, 10 and 12 weeks after the intervention. Method of measurement: Cell counter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAziz Eghbali
Iran University of Medical Sciences
Outcome results
None listed